2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2324

Metabolic Syndrome and Early Arthritis: Frequency, Association with Antibodies Profile and Disease Activity
Abstract Number: 2325

High Intensity Interval Training Improves Rheumatoid Arthritis Cardiorespiratory Fitness and Systemic Inflammation in Association with Alterations in Skeletal Muscle Metabolomic Profiles
Abstract Number: 2326

Prognostic Markers for Preclinical Cardiovascular Disease in Rheumatoid Arthritis and Correlation with Disease Activity
Abstract Number: 2327

Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors and the Role of Auto-antibodies
Abstract Number: 2328

In Rheumatoid Arthritis, New-onset Prednisone Use Is Associated with a Daily Dose, Cumulative Dose, and Duration-dependent Risk for Cardiovascular Events at 6 Months and 1 Year of Use
Abstract Number: 2329

Do Myocardial Inflammation and Microvascular Dysfunction in RA Lead to Adverse Changes in Left Ventricular Structure and Function over Time? A Longitudinal Analysis of Participants from Rheumatoid Arthritis: Study of the Myocardium
Abstract Number: 2330

Factors Associated with Differing Types of Heart Failure in Patients with Rheumatoid Arthritis
Abstract Number: 2331

Association of Rheumatoid Arthritis-related Autoantibodies with Pulmonary Function Test Abnormalities in a Prospective Rheumatoid Arthritis Registry
Abstract Number: 2332

Cardiovascular Risk Factors in Rheumatoid Arthritis: Prevalence, Comparison of Risk Calculators and Subclinical Atherosclerosis in Indian Patients
Abstract Number: 2333

Risk of Incident Myocardial Infarction Among Disabled Patients with Rheumatoid Arthritis Who Were Beneficiaries of the Social Security Disability Insurance
Abstract Number: 2334

Is Cardiovascular Risk and Mortality in Rheumatoid Arthritis Compared to Diabetes Mellitus and the General Population Overestimated?
Abstract Number: 2335

Prediction of Myocardial Fibrosis in Rheumatoid Arthritis Assessed by Cardiac Magnetic Resonance Imaging Using Artificial Neural Networks Models
Abstract Number: 2336

Levels of Proinflammatory Cytokines in Rheumatoid Arthritis Patients with Carotid Plaque: A Case-Control Study
Abstract Number: 2337

Treat to Target Is Not Linked to Best Myocardial Strain Indices: Is There Really a Myocardial Dysfunction Directly Associated with Disease Activity?
Abstract Number: 2338

Validation of a Claims Algorithm to Identify Interstitial Lung Disease in Patients with Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].